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Abstract: 
The aim of this study was to investigate the possible effects of 
corticosteroids in women with systemic lupus erythematosus (SLE) in two 
processes of executive function: cognitive flexibility and decision-making. 
To that end, we evaluated 121 women divided into three groups: 50 
healthy women, 38 women with SLE not receiving corticosteroid treatment 
and 33 women with SLE receiving corticosteroid treatment. Cognitive 
flexibility was measured with the Trail Making Tests A and B; decision-
making was measured with the Iowa Gambling Task. Additionally, 
demographic (age and education level), clinical (SLEDAI, SDI and disease 
duration) and psychological characteristics (stress vulnerability, perceived 
stress and psychopathic symptomatology) were evaluated. The results 
showed that both SLE groups displayed poorer decision-making than the 
healthy women (p = 0.006) and also that the SLE group receiving 
corticosteroid treatment showed lower cognitive flexibility than the other 
two groups (p = 0.030). Moreover, they showed the poorest scores on the 
following SCL-90-R subscales: somatisation (p = 0.005), obsessions and 
compulsions (p = 0.045), depression (p = 0.004), hostility (p = 0.013), 
phobic anxiety (p = 0.005), psychoticism (p = 0.016) and positive 
symptom total (p = 0.001). Additionally, they were more vulnerable to 
stress (p = 0.000). These findings help to understand the effects of 
corticosteroid treatment on cognitive flexibility and decision-making, in 
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addition to the disease-specific effects suffered by women with SLE. 
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Abstract 
The aim of this study was to investigate the possible effects of corticosteroids in women 
with systemic lupus erythematosus (SLE) in two processes of executive function: 
cognitive flexibility and decision-making. To that end, we evaluated 121 women 
divided into three groups: 50 healthy women, 38 women with SLE not receiving 
corticosteroid treatment and 33 women with SLE receiving corticosteroid treatment. 
Cognitive flexibility was measured with the Trail Making Tests A and B; decision-
making was measured with the Iowa Gambling Task. Additionally, demographic (age 
and education level), clinical (SLEDAI, SDI and disease duration) and psychological 
characteristics (stress vulnerability, perceived stress and psychopathic symptomatology) 
were evaluated. The results showed that both SLE groups displayed poorer decision-
making than the healthy women (p = 0.006) and also that the SLE group receiving 
corticosteroid treatment showed lower cognitive flexibility than the other two groups (p 
= 0.030). Moreover, they showed the poorest scores on the following SCL-90-R 
subscales: somatisation (p = 0.005), obsessions and compulsions (p = 0.045), 
depression (p = 0.004), hostility (p = 0.013), phobic anxiety (p = 0.005), psychoticism (p 
= 0.016) and positive symptom total (p = 0.001). Additionally, they were more 
vulnerable to stress (p = 0.000). These findings help to understand the effects of 
corticosteroid treatment on cognitive flexibility and decision-making, in addition to the 
disease-specific effects suffered by women with SLE. 
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Keywords  
Corticosteroids, executive function, flexibility, decision-making, systemic lupus 
erythematosus (SLE) 
Introduction 
Patients with systemic lupus erythematosus (SLE) show a diverse symptomatology that 
manifests on both organic and neuropsychiatric levels. Its prevalence is slightly below 
1:1000 in women and is tenfold lower in men.1-3 
 The decision to treat SLE with corticosteroids depends on the symptomatology, 
activity and severity of the disease. However, while corticosteroid treatment is 
indispensible for controlling the disease in some cases, it does produce adverse effects, 
some of which can lead to major organ damage. 1,4,5  
 The adverse effects of corticosteroid treatment and organ damage in SLE 
patients have been broadly studied and reviewed and reveal major implications.5-7 A 
few of the most characteristic side effects are adrenal damage (which affects the 
thyroid), cardiovascular damage (hypertension or myocardial infarction), bone fractures, 
infections, cataracts, mood swings and sleep disorders.  
 The possible cognitive effects of corticosteroid use have also been studied. The 
majority of these studies have found no association between corticosteroid use and 
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cognitive deficits in SLE patients.8-14 To the best of our knowledge, only one study has 
identified corticosteroid use as a factor associated with cognitive impairment in SLE. 
This study followed SLE patients for three years, and made evaluations every four 
months. These evaluations included standard medical history, physical examinations 
and cognitive testing. The results show that prednisone use was a factor associated with 
decreased cognitive function in SLE patients, as well as the presence of positive 
antiphospholipid antibodies, diabetes, increased depression and a lower education level. 
A few of the processes measured by Automated Neuropsychological Assessment 
Metrics (ANAM) were working memory, attention, non-verbal memory and 
visuospatial perception.15 
 Possible cognitive impairment in SLE patients has also been studied and 
associated with other variables linked to the disease itself or to the patients’ 
psychological condition. The majority of these studies did not find any association 
between cognitive impairment and clinical characteristics such as disease activity, 
disease duration or neuropsychiatric manisfestations.10 An association was found, 
however, between psychological characteristics, such as stress, anxiety and depression, 
and cognitive impairment in SLE patients, namely with total attention accuracy, 
immediate visual memory, delayed visual memory and visual fluency, where greater 
stress indicated dysfunction in these processes.2,16-18 Moreover, research findings show 
that SLE patients with cognitive impairment had affected verbal and visuospatial 
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memory and visuoconstructional abilities associated with neuropsychiatric 
manifestations. This cognitive impairment was not associated with disease activity, 
disease duration or corticosteroid use. 10 
Even though cognitive deficits and neuropsychiatric symptoms in SLE have 
been studied broadly, the possible effects of corticosteroid use on other aspects of 
executive function in SLE patients, such as flexibility and decision-making, have not. 
Various studies do show an association, however, between corticosteroid use and 
impairment in executive function (inhibition, working memory, shifting and 
planning,)19 thus showing that corticosteroid use does have negative effects on working 
memory and the hippocampus, which in some cases leads to cerebral atrophy, regardless 
of dose and treatment duration or disease activity.20,21 Only one study has compared 
SLE patients receiving corticosteroid treatment with others not receiving corticosteroid 
treatment and healthy women. They found that the patients receiving corticosteroid 
treatment have greater cerebral atrophy than healthy women. Furthermore, SLE patients 
receiving corticosteroid treatment display more severe cerebral atrophy than patients 
without SLE who receive corticosteroid treatment, regardless of dose or treatment 
duration.22 
 In spite of these approximations, the effects of corticosteroid treatment on 
executive function in SLE patients have not been studied. Therefore, the aim of our 
research has been to study if corticosteroid use has any effects on cognitive flexibility 
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and decision-making in women with SLE when compared with healthy women. We 
hypothesise that women with SLE who receive corticosteroid treatment will display 
poorer decision-making and cognitive flexibility than women with SLE who do not 
receive corticosteroid treatment and healthy women. 
Material and methods 
Patients 
One hundred twenty-one women participated in this study. They were divided in three 
groups. Group 1 (HW) was composed of 50 healthy women who were recruited via 
posters and Internet. Group 2 (SLE-CT) consisted of 38 women with SLE receiving 
corticosteroid treatment; group 3 (SLE-noCT) included 33 women with SLE not 
receiving corticosteroid treatment. The inclusion criteria for the women with SLE were 
to meet at least four ACR Classification Criteria for Diagnosis of SLE, to be over 18 
years of age, to be literate and to not present any psychological disorders. Additionally, 
participants from the SLE-noCT group had to have not received corticosteroid treatment 
for at least one year previous to the study. All the participants with SLE were patients 
from the Systemic Autoimmune Disease Unit (Internal Medicine Service) at the 
University Hospital ‘Virgen de las Nieves’ and the Clinical Hospital ‘San Cecilio’ in 
Granada, Spain. The inclusion criteria for the healthy women comprising the control 
group were the same as those for the SLE groups, except that, additionally, they 
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presented no mental or physical illnesses. This information was obtained through a brief 
semi-structured interview conducted when the women contacted us to participate in the 
study.  
 The main socio-demographic, clinical (SLEDAI, SDI and years with SLE) and 
treatment variables data were collected and recorded from the women with SLE. All the 
patients could at least read and write, and none of them presented any associated mental 
illnesses at the time of the study. All these patients and the healthy women gave their 
signed informed consent to take part in this study, which was approved by the ethics 
committee at our hospital and carried out in compliance with the Helsinki Declaration. 
Data collection 
All instruments used in the study were adapted versions validated in a Spanish 
population. 
Trail Making Tests A and B (TMTA, TMTB). This is one of five stand-alone tests from 
the Delis-Kaplan Executive Function System (D-KEFS). 24 Trail Making Tests A and B 
are timed tests of cognitive flexibility and visual motor integration that assess speed in 
processing information, attention and cognitive flexibility. The score obtained after 
dividing TMTB by TMTA produces the cognitive flexibility index and is the best 
execution indicator for the TMT.25-28  
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Iowa Gambling Task (IGT). This computerized task has been used to assess decision-
making in a wide variety of studies.29 It simulates essential components of decision-
making common to everyday life, and the assessment of rewarding and punishing 
events under conditions of uncertainty and risk. In the task, subjects must choose among 
four decks of cards. The task is composed of five blocks, each comprising twenty trials. 
Two decks provide a high and immediate gain but great future losses (long-term loss), 
while the other two decks provide lower immediate gains but a smaller future loss 
(long-term gain). The purpose of the task is to try to earn as much money as possible 
and to incur minimal losses when it is impossible to win. Initially, participants do not 
know these deck characteristics, but the program provides feedback about the 
consequences of each choice made by the participants.30 
Stress Vulnerability Inventory (SVI). The SVI consists of 22 items and evaluates the 
individual’s predisposition to be affected by perceived stress.31 The Spanish adaptation 
shows a Cronbach’s alpha of 0.87.32 As for convergent validity, the results show a 
significant positive correlation (p<0.01) with the following assessment scales: STAI-R, 
Beck Depression Inventory, Somatic Symptom Scale and Survey of Recent Life 
Experiences (SRLE). 
Perceived Stress Scale (PSS). The PSS is a self-report scale used to evaluate perceived 
stress levels and the degree to which people find their lives unpredictable, 
uncontrollable or overwhelming (aspects that contribute to stress).33,34 It consists of 14 
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items with five response alternatives. The highest score corresponds to the highest 
perceived stress level. The Spanish version of the PSS (14 items) has adequate 
reliability (internal consistency=0.81 and test-retest=0.73), concurrent validity and 
sensitivity. Here, we have considered those scores over 22 (i.e. the mean score for the 
Spanish population) as reflecting high levels of perceived stress.34 
SCL-90-R Symptoms Inventory.35-36 We used this instrument to rule out potential 
psychopathology in the participants. This self-report questionnaire was developed to 
assess symptoms of psychopathology and it includes 90 items with five response 
alternatives (0-4) on a Likert scale. Subjects respond according to how they have felt 
within the past seven days, including the day the inventory is administered. The 
inventory is scored and interpreted according to nine main dimensions (somatisation, 
obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, paranoid ideation, and psychoticism) and three global indices 
of psychological distress (Global Severity Index (GSI), Positive Symptom Total (PS), 
and Positive Symptom Distress Index (PSDI)). In this study, we have analysed these last 
three global indices. This instrument is thought to have satisfactory reliability and 
validity.36 
The SLE Disease Activity Index (SLEDAI). The SLEDAI was used to assess lupus 
activity.37 It consists of 24 descriptors with pre-assigned severity weights. The total 
SLEDAI score can range from 0 (no activity) to 105 (maximum activity). The SLEDAI 
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has been shown to be sensitive to changes in lupus activity measured by the treating 
physician. 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology 
(SLICC/ACR) Damage Index (SDI). The SDI is a physician-rated index that assesses 
cumulative organ damage due either to the disease or to complications of therapy.38 It 
includes 12 categories: ocular, neuropsychiatric, renal, pulmonary, cardiovascular, 
peripheral vascular, gastrointestinal, muscular-skeletal, skin, premature gonad failure, 
diabetes and cancer. Total scores range from 0 (no damage) to 48 (maximum damage).  
Procedure 
All the participants were scheduled individually at the Mind, Brain and Behaviour 
Research Centre at the University of Granada, Spain. Upon arrival to the laboratory they 
gave their signed informed consent. Their socio-demographic variables were then 
collected before carrying out the executive function tasks: the TMT (cognitive 
flexibility) and the IGT (decision-making). Subsequently, the psychological and stress 
tests were administered (SVI, SSP and SCL-90-R). Each session lasted approximately 
one and a half hours. 
Statistical analyses 
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Results are presented as mean and standard deviation. To begin, ANOVAs were used 
for examining socio-demographic differences (age and education level) among the three 
groups (healthy women, SLE patients receiving corticosteroid treatment and SLE 
patients not receiving corticosteroid treatment). Also, Student’s t-tests were used for 
comparing the clinical characteristics of SLEDAI, SDI and disease duration between 
both SLE groups. In addition, various ANOVAs were carried out for analysing 
differences in psychological variables (SVI, PSS and SCL-90-R) among all three 
groups. The independent variables were the three groups, i.e. healthy women, SLE 
patients receiving corticosteroid treatment and SLE patients not receiving corticosteroid 
treatment; the dependent variables were the scores on the SVI, PSS, and the SCL-90 
subscales. 
 Finally, one-way ANOVAs were administered with the TMT (for cognitive 
flexibility) and the IGT (for decision-making) in order to check for any statistically 
significant differences in executive function between the three groups. Education level 
and SLEDAI were used as a covariate, as the groups were not evenly weighted in these 
variables, which can be closely tied to executive function. Differences were considered 
significant when p = 0.05. Additionally, correlation analyses were used to test the 
relationship between the psychological stress variables and executive function variables 
in each group, and correlation analyses were used to test the relationship between the 
SLEDAI and the cognitive performance variables.  
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Results 
Participants’ socio-demographic and clinical characteristics 
Socio-demographic and clinical data for the participants can be found in Table 1. The 
results showed statistically significant differences in education level and SLEDAI.  
TABLE 1 
Psychological characteristics  
Table 2 shows psychological characteristics for the three groups. The results showed 
statistically significant differences in SVI (p < 0.001) among the three groups. The SLE-
CT group is the most vulnerable to stress (11.33 ± 4.87), followed by SLE-noCT (8.74 
± 5.11) and finally by the healthy women (5.96 ± 3.77). 
 There were significant differences in the SCL-90 R results for the healthy 
women when compared with the SLE groups. Both SLE groups scored higher than the 
healthy women in the following sub-scales: somatisation (p = 0.005), obsessions and 
compulsions (p = 0.045), depression (p = 0.004), hostility (p = 0.013). In phobic anxiety 
(p = 0.005), psychoticism (p = 0.016) and positive symptom total (p = 0.001) the SLE-
CT group scored higher than SLE-noCT and healthy women. 
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TABLE 2 
Executive function 
The results showed statistically significant results on the IGT (decision-making) 
between both SLE groups and healthy women (p = 0.006). Healthy women (4.08 ± 
20.38) scored higher on the decision-making task than SLE-CT (-7.13 ± 18.62) and 
SLE-noCT (-9.00 ± 23.35) (Figure 1). As the negative value indicates, SLE patients 
show poorer decision-making regardless of corticosteroid use.  
FIGURE 1 
 Figure 2 shows the decision-making scores from each of the five trials for the 
three groups.  
FIGURE 2 
 Regarding cognitive flexibility, the results showed statistically significant 
differences on the TMT B/A (cognitive flexibility) among the three groups (p = 0.030). 
SLE-CT (2.57 ± 0.90) showed poorer scores than SLE-noCT (2.18 ± 0.65) and healthy 
women (2.06 ± 0.60) (Figure 3). 
FIGURE 3 
 Finally, no significant correlations were found among psychological stress, 
psychopathology, SLEAI and SDI or the executive function variables.  
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Discussion 
The aim of this research was to investigate if corticosteroid use is associated with 
impairment in two processes of executive function, i.e. cognitive flexibility and 
decision-making. 
 To this end, women with SLE receiving corticosteroid treatment, women with 
SLE not receiving corticosteroid treatment and healthy women were evaluated by 
testing cognitive flexibility and decision-making by using the Trail Making Test and the 
Iowa Gambling Task, respectively, while controlling for other variables such as the 
socio-demographic, clinical and psychological characteristics as well as disease-specific 
variables. 
 The results showed that women with SLE make poorer decisions than healthy 
women, regardless of corticosteroid use. This conduct, therefore, cannot be attributed to 
the medication. Notwithstanding, when comparing women with SLE receiving 
corticosteroid treatment with others who are not and with healthy women, a statistically 
significant difference does exist, namely that the first group scores the lowest. These 
results are in line with another study in which SLE patients scored higher than the 
control group on the TMTA and TMTB, thus displaying worse task execution.11 This 
also supports various studies reporting that corticosteroid use decreases both declarative 
and working memory, due to the atrophy it brings about in the hippocampus,41,42 and 
Page 16 of 33
http://mc.manuscriptcentral.com/lupus
LUPUS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Corticosteroids, executive function and lupus 
E Montero-López et al. 
14 
 
that this decrease is reversible by lowering the dose or stopping corticosteroid treatment 
altogether.39,40  
 The results show lower decision-making scores for both SLE groups. 
Consequently, we can infer that it is the disease itself and its effects on the nervous 
system that may be affecting a poor task execution. On the other hand, factors such as 
disease activity could also be affecting these results. This parameter, however, did not 
correlate with decision-making or cognitive flexibility in our study. Therefore, decision-
making cannot be attributed to disease activity. In this regard, our data coincide with 
those of other studies reporting that SLEDAI is not a predictive factor of cognitive 
deficit in SLE.43,44 It is related indirectly, however, as SLEDAI is a marker of lupus 
activity, which in some instances requires corticosteroids, a treatment component used 
for decreasing disease activity. Therefore, controversy remains regarding an association 
between cognitive impairment and markers of disease activity,11,45 as some studies find 
an association,11,46 while others, such as ours, do not.43,44,47 
 Regarding psychological conditions, there were differences in the majority of the 
stress and psychopathic symptoms variables between the women with SLE and the 
healthy women. These results can be expected however, because individuals suffering 
from a chronic disease experience pain, disability, major side effects from treatment and 
unpredictable aggravation of the disease, all of which can be extremely stressful and 
produce anxiety and depression. These results are consistent with other studies that 
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report stress, anxiety and depression as possible factors that deteriorate symptomatology 
and quality of life in SLE patients.17,18,48,49 
 When considering the present study and its findings, there are a few limitations 
that need to be taken into account. This is the first study to analyse the effects of 
corticosteroids on executive function in women with SLE. In future studies more 
executive function parameters should be included with a similar sample, such as 
behaviour production, working memory, planning and inhibition, in order to assess if 
there are differences in the remaining executive function processes between women 
with SLE who receive corticosteroid treatment and others who do not receive 
corticosteroid treatment. Additionally, our groups did not share the same education 
levels, however, as this could be important, we did make sure to control for this factor. 
This variable was included as a co-variable in the TMT and IGT analyses among 
groups, as we are aware that some studies identify a lower education level as a factor 
associated with cognitive degeneration in SLE patients.10 At any rate, it is important to 
highlight the inherent difficulty in achieving equality in clinical populations. 
 In conclusion, the results from our study show that women with SLE display 
broader psychopathological symptoms, greater vulnerability to stress and poorer 
decision-making when compared with healthy women. Furthermore, as cognitive 
flexibility is lower in women with SLE who receive corticosteroid treatment than in 
healthy women and in women with SLE who do not receive corticosteroid treatment, 
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the adverse effects of corticosteroid treatment on the cognitive flexibility of the first 
group should be considered. Whereas most studies have limited their research to the 
physical effects of corticosteroid treatment, the findings from our study are useful for 
studying the neuropsychological effects of corticosteroid treatment, as they provide 
more information regarding side effects, such as poorer decision-making and cognitive 
flexibility. 
 Poor decision-making and diminished cognitive flexibility entail a series of 
clinical implications for patients that concern doctors, as well as patients and their 
families, such as inadequate adherence to treatment plans or difficulties making the 
necessary changes to effectively deal with the disease. These findings are important for 
the specialised medical professionals caring for these patients, because a better 
understanding of these cognitive deficits can make a substantial advance towards 
understanding and even solving some of the different problems encountered on a daily 
basis.  
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Table 1 Demographic and clinical characteristics in healthy women, SLE-noCT and SLE-CT 
 
 
Variable 
 
   
 
  HW  
Mean (SD) 
(n=50) 
 
 
SLE-noCT 
Mean (SD) 
 
(n=38) 
 
SLE-CT 
Mean (SD) 
 
(n=33) 
 
   p* 
 
   Post hoc 
 
Age 
 
36.30 
(10.76) 
 
38.63 (9.28) 
 
34.33 (11.39) 
 
0.225 
 
   - 
Education, years 14.92 (3.14) 15 (3.32) 11.67 (3.55) 0.001** SLE-
CT<SLE-
noCT=HW 
 
SLEDAI      - 1.03 (1.28) 2.59 (3.17) 0.013* SLE-
CT>SLE-
noCT 
SDI      - 0.22 (0.66) 0.38 (0.73) 0.370    - 
Disease duration, 
years 
Prednisone 
dosage mg/day       
     - 
     - 
 
  
9.92 (8.63) 
     - 
8.12 (5.92) 
 
6.35 (2.74) 
0.362 
    - 
   -   
   - 
 
       Data are expressed as mean (S.D.). **p ≤ 0.01. *p ≤ 0.05 
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Table 2 Psychological characteristics, in healthy women, and SLE-noCT and SLE-CT 
 
 
 
Variable 
 
      
 
                       HW 
                     (n=50) 
 
 
          SLE-noCT 
               (n=38) 
 
              SLE-CT 
                 (n=33) 
 
p 
 
    Post hoc 
 
Perceived 
Stress-Scale 
 
22.68 (8.20) 
 
 
26.32 (8.33) 
 
26.56 (8.20) 
    
   0.052 
 
 
 
Stress 
Vulnerability 
Inventory 
 
 
5.96 (3.77) 
 
 
8.74 (5.11) 
 
 
11.33 (4.87) 
 
   
0.001** 
 
SLE-
CT>SLE-
noCT>HW 
 
Symptom Checklist SCL-90-R 
  
 
 
Somatization 
 
 
52.80 (9.31) 
 
 
58.24 (8.01) 
 
 
59 (10.11) 
 
    
  0.005* 
 
SLE-
CT=SLE-
noCT>HW 
 
Obsessions 
and 
compulsions 
 
 
55.40 (11.34) 
 
 
59.65 (7.33) 
 
 
60.62 (9.84) 
 
    
  0.045* 
 
SLE-
CT=SLE-
noCT>HW 
 
Interpersonal 
sensitivity 
 
 
54.12 (11.44) 
 
 
53.65 (10.95) 
 
 
57.92 (10.24)  
 
    
   0.266 
 
 
 
Depression 
 
 
49.30(10.30) 
 
 
54.97 (9.12) 
 
 
56.69 (11.08) 
 
    
  0.004* 
 
SLE-
CT=SLE-
noCT>HW 
 
Anxiety 
 
 
52.24 (9.72) 
 
 
55.46 (8.27) 
 
 
57.38 (10.10) 
 
   
   0.060 
 
 
 
Hostility 
 
 
48.72 (9.81) 
 
 
54.41 (9.08) 
 
 
54.62 (11.92) 
 
   
  0.013* 
 
SLE-
CT=SLE-
noCT>HW 
 
Phobic 
Anxiety 
 
 
43.20 (11.62)  
 
 
45.43 (12.86) 
 
 
53.12 (12.82) 
 
   
  0.005* 
 
SLE-
CT>SLE-
noCT=HW 
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Paranoia 53.72 (12.91) 52.86 (11.97) 50.92 (10.30)    0.603 
 
 
Psychoticism 
 
 
48.72 (13.19) 
 
 
53.73 (11.07) 
 
 
56.96 (11.66) 
 
    
  0.016* 
 
SLE-
CT>SLE-
noCT=HW 
 
Global 
Severity 
Index 
 
 
42.40 (8.13) 
 
 
43.57 (3.54) 
 
 
45.12 (5.65) 
 
   
 0.214 
 
 
Positive 
Symptom 
Distress 
Index 
 
 
55.36 (12.23) 
 
 
60.70 (9.18) 
 
 
59.85 (10.31) 
 
  
  0.055 
 
 
Positive 
Symptom 
Total 
 
 
45.58 (9.20) 
 
 
48.92 (7.73) 
 
 
53.62 (10.07) 
 
    
0.001** 
 
SLE-
CT>SLE-
noCT=HW 
            Data are expressed as mean (S.D.) **. p ≤ 0.01. *. p ≤ 0.05 
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Figure 1 Making decision total in healthy women, and SLE-noCT and SLE-CT 
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Figure 2 Decision-making in healthy women, SLE-noCT and SLE-CT  
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Figure 3 Cognitive flexibility in healthy women, and LES SIN and SLE-CT 
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